Mutations of KRAS and BRAF are mutually exclusive in pancreatic cancers, which suggest that the activating mutations of these genes can compensate for each other in pancreatic cancer phenotypes (7). The gene discussed is KRAS; the disease is familial pancreatic carcinoma.